Press release

Cynosure Receives Clearance for Treatment Vocal Cord Dysplasia

Voice-Sparing Procedure Treats Disease In-Office Without Removal of Vocal Cords or Radiation Therapy

Florence, November 25th 2003 - Cynosure, Inc., a leading developer of medical lasers today announced the Regulatory clearance for the treatment of vocal cord dysplasia using the Pulse Dye Laser [PDL].

A revolutionary advancement over current methods, most pulse dye laser patients can be treated in the outpatient clinic, using only local anesthesia. This novel procedure allows treatment of these lesions without removal of or damage to the underlying vocal cords, and without the attendant risks of general anesthesia.

“We are thrilled with this clearance and the opportunities it provides for Cynosure in a new market. The PDL for dysplasia fulfills the aspirations of any medical technology, taking a 20-year-old technology and applying it in a novel way. It improves the standard of care by improving patient outcomes, with a less risky procedure, and in a cost effective manner, ”said Michael Davin, CEO of Cynosure, Inc.

Without treatment, 20-40% of those with moderate vocal cord dysplasia progress to cancer. Symptoms typically start as persistent and progressive hoarseness and eventually lead to loss of voice. The standard of care is currently either surgical removal of the disease, or radiation therapy. Both options are associated with significant side effects, permanent hoarseness or loss of voice.

A clinical study, “585-nm Pulsed Dye Laser Treatment of Glottal Dysplasia”, published in the September issue of Annals of Otology, Rhinology & Laryngology, showed significant reduction (80% of subjects had greater than 70% reduction in lesion size) of glottal dysplasia treated with the [PDL]. The PhotoGenica SV Pulse Dye Laser [PDL] selectively targets and eradicates the lesion’s blood supply without harm to surrounding tissue. The PDL’s selectivity, and the treatment delivery through a flexible optical fiber allow in-clinic treatment using only local anesthetic. The study was conducted at the Voice Disorders Center of the Massachusetts Eye and Ear Infirmary, under the direction of Dr. Steven Zeitels.

El.En., an Italian company, is the parent of a high-.tech industrial group operating in the optoelectronics sector. Based on proprietary technology and multidisciplinary know-how, the El.En Group manufactures laser sources (gas, solid-state and liquid) and innovative laser systems for medical and industrial applications.

The El.En. Group is the laser market leader in Italy and among the top operators in Europe. It designs, manufactures and sells worldwide:

- *Medical laser equipment used in dermatology, plastic surgery, physiotherapy, dentistry and gynecology.*
- *Industrial laser systems for applications ranging from cutting, marking and welding metals, wood, plastic and glass to decorating leather and textiles and restoring/conserving artworks.*

EL.EN has been listed on the NM since December 2000. Its market floatation is approximately 30% and its market capitalization amounts to €74 million.

Cod. ISIN: IT0001481867
Sigla: ELN
Negoziata su TAH
Mkt capt.: 70 mln/Euro
Cod. Reuters: ELN.MI
Cod. Bloomberg: ELN.IM

For further information:

El.En. SPA	**POLYTEMS HIR**	**POLYTEMS HIR**
Enrico ROMAGNOLI	Rita CAMELLI	Bianca FERSINI MASTELLONI
Investor Relator	Ufficio Stampa	Comunicazione Finanziaria
Tel. 055-8826807	Tel. 335-439571	Tel. 06-6797849/69923324
finance@elen.it	r.camelli@polytemshir.it	b.fersini@polytemshir.it